Vice President of Product Management and Market Development for the Clinical Sequencing Division; Thermo Fisher Scientific
BIOGRAPHY
MAR 30, 2022 6:00 AM PDT
Announcing the launch of the Genexus Dx Integrated Sequencer (CE-IVD) - nucleic acid to NGS report in as little as 24 hours
Speakers
-
Dr. Luca Quagliata, PhD, BCMAS
Vice President, Medical Affairs; Thermo Fisher ScientificBIOGRAPHY -
Kathy Davy
Vice President of the Translational and Clinical Oncology in the Clinical Sequencing Division, Thermo Fisher ScientificBIOGRAPHY
Event Date & Time
Date: March 30, 2022
Time: 3:00pm CET
Time: 3:00pm CET
Abstract
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic sequencing with faster turnaround times, reduced tumor specimen requirements and increased ease of use, requiring less training and hands on time. As a result, NGS has now been become accessible to a broad spectrum of laboratories bringing testing closer to the patient. Instruments and instrument consumables must meet the EU legislation for in vitro diagnostic (IVD) medical devices, In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746 going into effect May 26, 2022. Delivering on our mission to democratize NGS, make NGS accessible to all labs, Thermo Fisher Scientific is proud to announce the launch of the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer. Learn more about the Genexus Dx Integrated Sequencer that will allow you to go from nucleic acid to NGS report in as little as 24 hours.
Learning Objectives:
- Describe the Genexus Dx Integrated Sequencer and sequencing within 24 hours
- Demonstrate the importance of fast NGS for clinics
- Deploy Thermo Fisher Scientific’s clinical sequencing commitment on IVDR
Webinars will be available for unlimited on-demand viewing after live event.